

Application Ser. No.: 10/040,370
Filing Date: January 09, 2002
Examiner: Venkataraman Balasubramanian

Remarks

In the Office Action, dated February 11, 2004, the Examiner noted that claims 1, 2, 4-15, 18-26, 28, 29 and 31-35 are pending in the application; and that claims 1, 2, 4-15, 18-26, 28, 29 and 31-35 are finally rejected. By this amendment, claims 1, 2, 5, 10, 15 and 26 have been amended. Thus, claims 1, 2, 4-15, 18-26, 28, 29 and 31-35 are pending in the application. Further, in response to Applicants' response dated, July 12, 2004, the Examiner has issued an Advisory Action, dated, July 29, 2004 indicating that the claims as amended may overcome all of the outstanding rejection except for the non-elected subject matter which is still present in certain of the pending claims. As a result, Amendments to claims 1 and 2 further considered the points raised by the Examiner in his Advisory Action, dated July 29, 2004. No new subject matter has been inserted through these amendments. All of the amendments are fully supported by the specification and are discussed further in detail below.

Claim 1 is amended to obviate the outstanding rejections and to place the application in condition for an allowance. Further, certain of the non-elected subject matter has been deleted from claims 1 and 2 per advisory action issued by the Office on July 29, 2004. Claims 5, 10, 15 and 26 are amended to correct certain obvious typographical errors. Specifically, in claim 5 a missing "," has been inserted after alkylcarbonyl at penultimate line of the claim; in claims 15 and 26 the compound name appeared as "N-m.tolyl" which is amended to correctly read as "N-m-tolyl." Similarly, claim 10 was amended to correct the typographical error of the word "unsubstituted." The Examiner's rejections are respectfully traversed below.

Comments on Advisory Action:

As noted, the Office issued an Advisory Action, dated July 29, 2004 in response to Applicants' response of July 12, 2004. In the Advisory Action, the Examiner indicated that applicants' amendment may overcome the rejections of record except for the non-elected subject matter still present in the claims. As noted above, Applicants submit that only claims 1 and 2 still had certain non-elected subject matter, which have been deleted

Application Ser. No.: 10/040,370
Filing Date: January 09, 2002
Examiner: Venkataraman Balasubramanian

by way of this amendment. In view of this, it is respectfully submitted that claims 1, 2, 4-15, 18-26, 28, 29 and 31-35, as amended, are in condition for allowance and such an action is earnestly requested.


Conclusions

In view of the above Remarks, it is respectfully submitted that claims 1, 2, 4-15, 18-26, 28, 29 and 31-35 are now in condition for allowance and the early issuance of this case is respectfully requested. In the event the Examiner wishes to contact the undersigned regarding any matter, please call (collect if necessary) the telephone number listed below.

Applicants believe there are no fees due for this Rule 116 Supplemental Amendment. However, if the Examiner deems that fees are due, please charge these fees to Deposit Account No. 18-1982 for Aventis Pharmaceuticals Inc. Bridgewater, NJ. Please credit any overpayment to Deposit Account No. 18-1982.

Respectfully submitted,

Sept. 2, 2004



Balaram Gupta
Registration No. 40,009
Attorney for Applicants

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
MAIL CODE: BWD-303A
Bridgewater, NJ 08807-0800
Telephone: 908-231-3364
Telefax: 908-231-2626